Guidelines on the management of latent tuberculosis infection
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast maj...
| Autor principal: | |
|---|---|
| Autores Corporativos: | , , |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Geneva, Switzerland :
World Health Organization
[2015]
|
| Edición: | 1st ed |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009622068206719 |
Tabla de Contenidos:
- ""Cover""; ""Cover""; ""Contents""; ""Contents""; ""Acknowledgements""; ""Acknowledgements""; ""Abbreviations""; ""Abbreviations""; ""Declaration and management of conflict of interest""; ""Declaration and management of conflict of interest""; ""Executive summary""; ""Executive summary""; ""1. Background and process""; ""1. Background and process""; ""1.1. Background""; ""1.1. Background""; ""1.2. Scope of the guidelines""; ""1.2. Scope of the guidelines""; ""1.3. Target audience""; ""1.3. Target audience""; ""1.4. Development of the guidelines""; ""1.4. Development of the guidelines""
- ""1.5. Quality of evidence and strength of the recommendations""""1.5. Quality of evidence and strength of the recommendations""; ""2. Recommendations""; ""2. Recommendations""; ""2.1. Identification of at-risk populations for LTBI testing and treatment""; ""2.1. Identification of at-risk populations for LTBI testing and treatment""; ""2.1.1. Summary of the evidence""; ""2.1.1. Summary of the evidence""; ""2.1.2. Balance of benefits and harms""; ""2.1.2. Balance of benefits and harms""; ""2.1.3. Values and preferences of clients and health-care providers""
- ""2.1.3. Values and preferences of clients and health-care providers""""2.1.4. Resource considerations""; ""2.1.4. Resource considerations""; ""2.2. Algorithm to test and treat LTBI""; ""2.2. Algorithm to test and treat LTBI""; ""2.2.1. Summary of the evidence""; ""2.2.1. Summary of the evidence""; ""2.2.2. Balance of benefits and harms""; ""2.2.2. Balance of benefits and harms""; ""2.2.3. Values and preferences of clients and health-care providers""; ""2.2.3. Values and preferences of clients and health-care providers""; ""2.2.4. Resource considerations""; ""2.2.4. Resource considerations""
- ""2.3. Treatment options for LTBI""""2.3. Treatment options for LTBI""; ""2.3.1. Summary of the evidence""; ""2.3.1. Summary of the evidence""; ""2.3.2. Balance of benefits and harms""; ""2.3.2. Balance of benefits and harms""; ""2.3.3. Values and preferences of clients and health-care providers""; ""2.3.3. Values and preferences of clients and health-care providers""; ""2.3.4. Resource considerations""; ""2.3.4. Resource considerations""; ""2.4. Preventive treatment for contacts of MDR-TB cases""; ""2.4. Preventive treatment for contacts of MDR-TB cases""; ""2.4.1. Summary of the evidence""
- ""2.4.1. Summary of the evidence""""2.4.2 Balance of benefits and harms""; ""2.4.2 Balance of benefits and harms""; ""2.4.3. Values and preferences of clients and health-care providers""; ""2.4.3. Values and preferences of clients and health-care providers""; ""2.4.4. Resource considerations""; ""2.4.4. Resource considerations""; ""2.4.5. Conclusions""; ""2.4.5. Conclusions""; ""3. Issues in Implementation""; ""3. Issues in Implementation""; ""3.1. Adverse events monitoring""; ""3.1. Adverse events monitoring""; ""3.2. Risk of drug resistance following LTBI treatment""
- ""3.2. Risk of drug resistance following LTBI treatment""
